ClinConnect ClinConnect Logo
Search / Trial NCT00639301

Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 19, 2008

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

Survivor Quality Of Life Eye

ClinConnect Summary

The Retinoblastoma Survivor Study is looking to understand how surviving retinoblastoma, a type of eye cancer that usually affects children, impacts people's overall health and quality of life as adults. The study focuses on aspects like physical health, emotional well-being, and daily activities to see how these survivors feel about their lives. The goal is to gather valuable information that can help improve care for children diagnosed with retinoblastoma in the future, as well as offer better support for those who have survived it.

If you or someone you know was diagnosed with retinoblastoma at any age and has completed treatment at least five years ago, you may be eligible to participate in this study. Participants will have the chance to share their experiences and feelings about life after cancer, which could ultimately help others in similar situations. The study is open to all adults aged 65 to 74, and everyone who takes part will be asked to give their consent. This study is currently recruiting, so if you’re interested, it could be a great opportunity to contribute to important research!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patient diagnosed with retinoblastoma at any age
  • At least five years from completion of all retinoblastoma-directed therapy
  • Able to provide informed consent and/or assent, if indicated

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.

Locations

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Danielle Novetsky Friedman, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials